Mereo BioPharma Group/MREO

$2.81

0.72%
-
1D1W1MYTD1YMAX

About Mereo BioPharma Group

Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).

Ticker

MREO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Denise Scots-Knight

Employees

36

Headquarters

London, United Kingdom

MREO Metrics

BasicAdvanced
$370.28M
Market cap
-
P/E ratio
-$0.26
EPS
0.85
Beta
-
Dividend rate
$370.28M
0.85358
$4.36
$0.92
1.56M
3.106
8.032
16.126
-27.63%
-40.95%
-38.33%
41.991
4.754
9.098
-31.83%

What the Analysts think about MREO

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
104.27% upside
High $6.99
Low $3.99
$2.81
Current price
$5.74
Average price target

MREO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-154.92% profit margin
QuarterlyAnnual
Q2 23
QoQ growth
Revenue
£7.1M
∞%
Net income
£-11M
-26.67%
Profit margin
-154.92%
-∞%

MREO Earnings Performance

Earnings per share (EPS)

Company profitability
-
QuarterlyAnnual
Q4 23
Actual
-
Expected
-£0.00
Surprise
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Mereo BioPharma Group stock?

Mereo BioPharma Group (MREO) has a market cap of $370.28M as of April 24, 2024.

What is the P/E ratio for Mereo BioPharma Group stock?

The price to earnings (P/E) ratio for Mereo BioPharma Group (MREO) stock is 0 as of April 24, 2024.

Does Mereo BioPharma Group stock pay dividends?

No, Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders as of April 24, 2024.

When is the next Mereo BioPharma Group dividend payment date?

Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders.

What is the beta indicator for Mereo BioPharma Group?

Mereo BioPharma Group (MREO) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Mereo BioPharma Group stock price target?

The target price for Mereo BioPharma Group (MREO) stock is $5.74, which is 106.47% above the current price of $2.78. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Mereo BioPharma Group stock

Buy or sell Mereo BioPharma Group stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing